Monoclonal antibodies blocking CGRP for prevention of migraine
Introduction and purpose Monoclonal antibodies blocking calcitonin gene-related peptide (CGRP) are a novel treatment strategy developed specifically for prevention of migraine. Four drugs belong to this group: eptinezumab, fremanezumab and galcanezumab, which bind to the peptide; and erenumab, w...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2023-04-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/43098 |
| _version_ | 1827966692991434752 |
|---|---|
| author | Alicja Maziarczyk Dominika Miazga Laura Surdacka |
| author_facet | Alicja Maziarczyk Dominika Miazga Laura Surdacka |
| author_sort | Alicja Maziarczyk |
| collection | DOAJ |
| description |
Introduction and purpose
Monoclonal antibodies blocking calcitonin gene-related peptide (CGRP) are a novel treatment strategy developed specifically for prevention of migraine. Four drugs belong to this group: eptinezumab, fremanezumab and galcanezumab, which bind to the peptide; and erenumab, which blocks the CGRP receptor. CGRP is involved in nociception and plays a crucial role in the pathophysiology of migraine, as it is released in the trigeminal ganglion as a response to local cerebral vasoconstriction in order to cause dilation of the vessels and maintain cerebral blood flow. Moreover, administration of CGRP, especially among migraineurs, induces a migraine-type headache. The aim of the paper is to discuss the potential of monoclonal antibodies blocking CGRP for the prevention of migraine and to outline their safety and efficacy profile.
State of knowledge
Several randomised clinical trials have shown a significant efficacy of these drugs compared to placebo in reducing monthly migraine affected days, among patients suffering from both episodic and chronic migraine. Incidence rate of side effects is low; the most common were mild to moderate (e.g. pain at the injection site, upper respiratory tract infections, nasopharyngitis, back pain and urinary tract infection). Anti-CGRP monoclonal antibodies exhibit a superior benefit-to-risk ratio than established preventive treatments.
Conclusions
Randomized controlled trials are still needed in order to compare different anti-CGRP monoclonal antibodies and asses their long-term safety profile. In conclusion, these drugs seem to provide promising prospects of improving the lives of migraineurs. As based on current knowledge, the benefits are superior to the likelihood of harm.
|
| first_indexed | 2024-04-09T17:52:44Z |
| format | Article |
| id | doaj.art-94ec53f4c5fe42afa4c72a2bbedf3c3f |
| institution | Directory Open Access Journal |
| issn | 2391-8306 |
| language | English |
| last_indexed | 2024-04-09T17:52:44Z |
| publishDate | 2023-04-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj.art-94ec53f4c5fe42afa4c72a2bbedf3c3f2023-04-15T10:45:23ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062023-04-0118110.12775/JEHS.2023.18.01.005Monoclonal antibodies blocking CGRP for prevention of migraineAlicja Maziarczyk0Dominika Miazga1Laura Surdacka2Student, Wydział Lekarski, Uniwersytet Medyczny w LublinieStudent, Wydział Lekarski, Uniwersytet Medyczny w LublinieStudent, Wydział Lekarski, Uniwersytet Medyczny w Lublinie Introduction and purpose Monoclonal antibodies blocking calcitonin gene-related peptide (CGRP) are a novel treatment strategy developed specifically for prevention of migraine. Four drugs belong to this group: eptinezumab, fremanezumab and galcanezumab, which bind to the peptide; and erenumab, which blocks the CGRP receptor. CGRP is involved in nociception and plays a crucial role in the pathophysiology of migraine, as it is released in the trigeminal ganglion as a response to local cerebral vasoconstriction in order to cause dilation of the vessels and maintain cerebral blood flow. Moreover, administration of CGRP, especially among migraineurs, induces a migraine-type headache. The aim of the paper is to discuss the potential of monoclonal antibodies blocking CGRP for the prevention of migraine and to outline their safety and efficacy profile. State of knowledge Several randomised clinical trials have shown a significant efficacy of these drugs compared to placebo in reducing monthly migraine affected days, among patients suffering from both episodic and chronic migraine. Incidence rate of side effects is low; the most common were mild to moderate (e.g. pain at the injection site, upper respiratory tract infections, nasopharyngitis, back pain and urinary tract infection). Anti-CGRP monoclonal antibodies exhibit a superior benefit-to-risk ratio than established preventive treatments. Conclusions Randomized controlled trials are still needed in order to compare different anti-CGRP monoclonal antibodies and asses their long-term safety profile. In conclusion, these drugs seem to provide promising prospects of improving the lives of migraineurs. As based on current knowledge, the benefits are superior to the likelihood of harm. https://apcz.umk.pl/JEHS/article/view/43098CGRPmonoclonal antibodymigraineprevention |
| spellingShingle | Alicja Maziarczyk Dominika Miazga Laura Surdacka Monoclonal antibodies blocking CGRP for prevention of migraine Journal of Education, Health and Sport CGRP monoclonal antibody migraine prevention |
| title | Monoclonal antibodies blocking CGRP for prevention of migraine |
| title_full | Monoclonal antibodies blocking CGRP for prevention of migraine |
| title_fullStr | Monoclonal antibodies blocking CGRP for prevention of migraine |
| title_full_unstemmed | Monoclonal antibodies blocking CGRP for prevention of migraine |
| title_short | Monoclonal antibodies blocking CGRP for prevention of migraine |
| title_sort | monoclonal antibodies blocking cgrp for prevention of migraine |
| topic | CGRP monoclonal antibody migraine prevention |
| url | https://apcz.umk.pl/JEHS/article/view/43098 |
| work_keys_str_mv | AT alicjamaziarczyk monoclonalantibodiesblockingcgrpforpreventionofmigraine AT dominikamiazga monoclonalantibodiesblockingcgrpforpreventionofmigraine AT laurasurdacka monoclonalantibodiesblockingcgrpforpreventionofmigraine |